Comparison of First-Line FOLFOX versus FOLFIRI in RAS Mutant Metastatic Colorectal Cancer Patients

Objective: Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality, with rat sarcoma (RAS) and proto-oncogene B-raf (BRAF) mutations associated with worse prognosis in metastatic settings. Despite advances in treatment, the optimal chemotherapy backbone combined with bevaciz...

Descripción completa

Detalles Bibliográficos

Autores principales:	Alper TOPAL, Goncagül AKDAĞ, Ayşegül DUMLUDAĞ, Çağlar KÖSEOĞLU, Ömer Faruk KUZU, Hüseyin ATACAN, Baran Can AYTAÇ, Gizem YILDIRIM, Sedat YILDIRIM, Hacer Şahika YILDIZ, Gülsema YILDIRAN KESKİN, Nuri KARADURMUŞ
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Turkish Society of Oncology 2025-08-01
Colección:	Journal of Oncological Sciences
Materias:	colorectal cancer kras braf folfox folfiri bevacizumab
Acceso en línea:	https://journalofoncology.org/articles/comparison-of-first-line-folfox-versus-folfiri-in-ras-mutant-metastatic-colorectal-cancer-patients/doi/jos.galenos.2025.2025-3-22
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!